Last reviewed · How we verify
Taxanes plus Carboplatin
Taxanes work by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Carboplatin works by crosslinking DNA, causing cell death in rapidly dividing cancer cells.
Taxanes work by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Carboplatin works by crosslinking DNA, causing cell death in rapidly dividing cancer cells. Used for Non-small cell lung cancer, ovarian cancer, breast cancer, and other solid tumors.
At a glance
| Generic name | Taxanes plus Carboplatin |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Taxane and platinum-based chemotherapeutic agent |
| Target | Microtubules and DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Taxanes, such as paclitaxel and docetaxel, bind to tubulin and prevent microtubule depolymerization, thereby stabilizing microtubules and inhibiting cell division. Carboplatin, a platinum-based chemotherapeutic agent, forms platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. This combination therapy targets rapidly dividing cancer cells, making it effective in treating various types of cancer.
Approved indications
- Non-small cell lung cancer, ovarian cancer, breast cancer, and other solid tumors
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taxanes plus Carboplatin CI brief — competitive landscape report
- Taxanes plus Carboplatin updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI